Targeting FXR in cholestasis: hype or hope

Area of Science:

• Hepatology
• Cholestasis Research
• Bile Acid Signaling

Background:

• Bile acids, cholesterol metabolites, act as signaling molecules.
• Nuclear receptors like FXR and cell surface receptors (GP-BAR1) regulate bile acid homeostasis.
• FXR is a key sensor in bile acid metabolism and signaling networks.

Purpose of the Study:

• To evaluate the efficacy and side effects of a dual FXR/GP-BAR1 ligand in cholestasis models.
• To investigate the molecular mechanisms of side effects associated with dual FXR/GP-BAR1 ligands.
• To explore potential therapeutic strategies for severe cholestasis.

Main Methods:

• Utilized a semisynthetic bile acid derivative (6-ECDCA/obeticholic acid) as a dual FXR/GP-BAR1 ligand.
• Assessed the drug's effect on bile flow impairment in a cholestasis model.
• Analyzed clinical trial data for efficacy on surrogate markers and side effect profiles.

Main Results:

• The dual FXR/GP-BAR1 ligand attenuated bile flow impairment in a cholestasis model.
• Phase II trials showed beneficial effects on alkaline phosphatase in primary biliary cirrhosis.
• Dose-dependent itching occurred in up to 70% of patients, leading to discontinuation in 38%.

Conclusions:

• GP-BAR1 activation in the skin is identified as the cause of pruritus.
• FXR activation's role in severe cholestasis requires further confirmation.
• FXR antagonists present a potential therapeutic avenue for severe/obstructive cholestasis.